## 4 Discussion  
In this study, the addition of polymers such as Eudragit L100 and PVP K30 to supersaturated solution formulations significantly extended the nucleation induction time from 12 to about 64 h, demonstrating their effectiveness in stabilizing ritonavir (RTV). This extension is crucial for preventing the premature crystallization of RTV, thus maintaining its amorphous state and improving its bioavailability. The interaction between the polymers and RTV not only inhibits crystal nucleation but also contributes to a more stable drug environment, which is vital for the effectiveness of amorphous drug formulations. This stabilization mechanism is essential for drugs such as RTV, which have poor water solubility and can greatly benefit from enhanced solubility and delayed crystallization [52]. Integrating non-covalent adaptable networks (NANs) into a polymer-based system can enhance stabilization by adding layers of adaptability and reversibility to the drug-polymer interactions through non-covalent interactions (Figure 10). NANs, which utilize non-covalent interactions such as hydrogen bonding, electrostatic interactions, and hydrophobic interactions, can respond to environmental changes, allowing for more controlled drug release under physiological conditions [5]. This feature enhances the potential to tailor drug release profiles to meet specific therapeutic needs, reducing the likelihood of side effects associated with sudden drug release. Additionally, the adaptability of NANs supports the recovery and reuse of polymers, which is in line with sustainable pharmaceutical practices [8]. Furthermore, Figures 5 and 8 offer critical insights into the molecular mechanisms driving this stabilization. Figure 5, which compares the RDF data for Eudragit L100 and PVP K30, clearly shows that these polymers' effectiveness is concentration-dependent. PVP K30 performs better at lower concentrations, while Eudragit L100 demonstrates superior stabilizing effects at higher concentrations. These findings are corroborated by Figure 8, which tracks the hydrogen bond formation between riboavir and the polymers over time. Figure 10: An illustration of the dynamics of non-covalent adaptable networks (NANs) in drug–polymer systems [4; 53]. The data reveal that higher concentrations of Eudragit L100 result in more frequent and consistent hydrogen bonding, leading to the stronger stabilization of ritonavir. In contrast, PVP K30, while effective at lower concentrations, forms fewer hydrogen bonds, which explains its comparatively reduced performance at higher concentrations. These figures were updated to improve clarity, particularly Figure 5, where the overlapping data points made it difficult to distinguish between trends. The updated visuals clearly show the green curve, representing one of the polymers, which enhances the overall readability and enables a more precise comparison of polymer performance. This clarification reinforces the conclusion that PVP K30 excels at lower concentrations, whereas Eudragit L100 performs better at higher doses, aligning with the findings from the hydrogen bonding analysis shown in Figure 8.  
Integrating NANs into molecular dynamics simulations of drug-polymer interactions provides deep insights into the underlying mechanisms that enhance the stability and efficacy of amorphous solid dispersions (ASDs) [9]. This approach allows researchers to not only visualize but also optimize the formation and stability of these complex systems under various conditions. It further facilitates the identification of the optimal combinations of polymers and NANs that maximize drug stability and effectiveness within ASD formulations. Moreover, the adaptability of NANs introduces innovative capabilities into drug formulation technology, enhancing the efficiency and scalability of manufacturing processes [23]. Incorporating NANs into ASD formulations could redefine the synergy between drugs and polymers, particularly for traditional polymers such as Eudragit L100 and PVP K30.